GSK Pharma Delivers Strong Q2 FY27 Results Driven by Innovation and Established Portfolio
GlaxoSmithKline Pharmaceuticals Ltd 路 Transcript 路 08 Nov 2026, 7:12 pm
GSK Pharma Delivers Strong Q2 FY27 Results Driven by Innovation and Established Portfolio GSK India reported record Q2 FY27 revenue of INR 1,180 crore, up 21% YoY (underlying growth 12-13%), driven by healthy 5-7% GenMed volume growth. EBITDA rose 20% YoY to INR 400 crore with stable 34% margins, while PAT grew 33% YoY (underlying 21%), aided by an INR 42 crore one-off tax refund interest. The balance sheet remained zero-debt with INR 2,200 crore cash and a 98% cash conversion ratio. The innovation portfolio reached 7% of revenues, supported by Shingrix doubling sales. Blenrep is scheduled to launch in Q3.
Original exchange filing (PDF)
More announcements from GlaxoSmithKline Pharmaceuticals Ltd
- As per attachment 路 05 Nov 2026
- As per attachment 路 05 Nov 2026
- Analyst meet Presentation 路 04 Nov 2026
- As per attachment 路 04 Nov 2026
- As per attachment 路 04 Nov 2026
- As per attachment 路 04 Nov 2026
- outcome of Meeting 路 04 Nov 2026
- GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 04 Nov 2026
